Dengue-2 Core
Protein is >90% pure as determined by 10% PAGE (coomassie staining).
Description
Recombinant Dengue-2 Core produced in E. coli having a molecular weight of 12kDa.
Dengue-2 Core is fused to a 6 amino acid His-tag at C-terminus & purified by proprietary chromatographic techniques.
Product Specs
Product Science Overview
Dengue virus (DENV) is a significant global health concern, causing millions of infections annually. The virus has four serotypes (DENV-1 to DENV-4), each capable of causing dengue fever and severe dengue hemorrhagic fever. The development of effective vaccines and therapeutic strategies against DENV is crucial. One of the promising approaches involves the use of recombinant proteins, such as the Recombinant Dengue-2 Core.
The core protein of Dengue virus serotype 2 (DENV-2) is a structural protein that plays a critical role in the virus’s life cycle. It is involved in the formation of the viral nucleocapsid, which encases the viral RNA genome. The core protein is highly conserved among different DENV serotypes, making it an attractive target for vaccine development.
Recombinant protein technology involves the expression of viral proteins in a host system, such as bacteria, yeast, or mammalian cells. This technology allows for the production of large quantities of viral proteins, which can be used for various applications, including vaccine development, diagnostic assays, and research studies.
The development of recombinant Dengue-2 Core involves cloning the gene encoding the core protein into an expression vector. This vector is then introduced into a host system, where the core protein is expressed and purified. The recombinant core protein can be used to study the immune response to DENV-2 and to develop vaccines that elicit protective immunity.
Recombinant Dengue-2 Core has shown promise in vaccine development. Studies have demonstrated that the core protein can induce strong immune responses, including the production of neutralizing antibodies and T-cell responses. These immune responses are crucial for providing protection against DENV-2 infection.
Despite the potential of recombinant Dengue-2 Core in vaccine development, several challenges remain. One of the main challenges is ensuring the stability and immunogenicity of the recombinant protein. Additionally, the development of a universal dengue vaccine that provides protection against all four serotypes is a significant challenge.
Future research should focus on optimizing the expression and purification of recombinant Dengue-2 Core, as well as evaluating its efficacy in preclinical and clinical studies. Advances in recombinant protein technology and a better understanding of the immune response to DENV will be critical in overcoming these challenges.
